Immunicum AB (1YG0) Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.49

-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.49

-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.35 - €0.71

Previous CloseN/A

Volume0.00

Average Volume (3M)16.00

Market Cap

€40.56M

Enterprise Value€322.08

Total Cash (Recent Filing)€59.88M

Total Debt (Recent Filing)€17.93M

Price to Earnings (P/E)―

Beta0.20

Next Earnings

Nov 11, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.79

Shares Outstanding64,784,580

10 Day Avg. Volume50

30 Day Avg. Volume16

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.14

Revenue Forecast (FY)€451.39K

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageVery low leverage limits fixed financial obligations and preserves flexibility for research spending or future financing. This is a relative strength for a clinical-stage biotech, although it does not offset the company’s lack of operating income.

Narrowing LossesThe reduction in losses suggests some progress in controlling the cost base and may extend the company’s financial runway. However, the improvement is not yet sufficient to establish profitability because revenue remains absent.

Improved Cash Burn Versus 2023Lower cash consumption than in 2023 indicates better spending discipline and could reduce near-term financing pressure. The benefit remains limited because operating and free cash flow are still negative and do not yet support self-funded operations.

Bears Say

No Recurring Revenue BaseThe absence of recurring revenue leaves the company dependent on external financing or potential collaboration payments. Without a reliable commercial income stream, operating costs cannot currently be absorbed by the business itself.

Persistent UnprofitabilityContinued operating and net losses show that the development-stage business has not reached economic sustainability. Persistent deficits can erode shareholder equity and increase reliance on future capital raises or strategic funding.

Ongoing Negative Cash FlowOngoing cash burn means the company is consuming resources without generating enough cash to fund operations. This creates continuing financing risk and may constrain investment in clinical development if external capital becomes less available.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.71 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €40.56M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Aug 20, 2026. The company reported -€0.041 earnings per share for the quarter, the consensus estimate of -€0.041 by €0.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate is -0.04.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 64,784,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.041 in its last earnings report, expectations of -€0.041. Following the earnings report the stock price went down -1.342%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.